Home Ovarian and Gynecologic Cancer Biomarkers HPV Test for Cervical Cancer: High-Risk HPV Types, Screening, and Follow-Up

HPV Test for Cervical Cancer: High-Risk HPV Types, Screening, and Follow-Up

By
Vita Library
-
46
Learn how high-risk HPV testing is used for cervical cancer screening, what positive and negative results mean, which HPV genotypes carry higher risk, and how colposcopy, cytology, and dual stain guide follow-up.

A high-risk HPV test checks a cervical or approved vaginal sample for human papillomavirus types that can cause cervical precancer and cancer. It is one of the main tools used for cervical cancer screening because persistent infection with a carcinogenic HPV type is the necessary cause of nearly all cervical cancers. A positive test does not mean cancer is present. It means a high-risk viral type was detected and the next step should be based on genotype, cytology or another triage test, age, and prior screening history. HPV 16 and HPV 18 carry especially high risk and usually trigger colposcopy. Other high-risk types may be managed with cytology, p16/Ki-67 dual stain, extended genotyping, or repeat HPV testing. A negative high-risk HPV result is strongly reassuring for average-risk people, although recommended screening still continues at guideline-based intervals. HPV testing is for screening and risk assessment; symptoms such as abnormal bleeding require diagnostic evaluation even after a recent negative test.

  • A positive high-risk HPV test means a carcinogenic HPV type was detected, not that cervical cancer has been diagnosed.
  • HPV 16 and HPV 18 generally require colposcopy because they carry the highest immediate and future cervical cancer risk.
  • Other high-risk HPV results are often triaged with cytology, extended genotyping, or p16/Ki-67 dual stain before deciding on colposcopy or 1-year follow-up.
  • A negative HPV test provides strong short-term reassurance, but the next screening interval depends on the testing method and personal history.
  • HPV testing can be clinician-collected, and selected FDA-approved screening pathways now allow self-collected vaginal specimens in health care settings.

Table of Contents

What the HPV Test Detects

High-risk HPV testing detects genetic material from carcinogenic human papillomavirus types. Depending on the assay, the target may be viral DNA or RNA. The test does not measure antibodies, and it is not a blood test.

HPV is common. Most sexually active people are exposed at some point, and most infections are cleared or suppressed by the immune system without causing cancer. The concern is persistent infection with a carcinogenic type. Over years, viral oncogene activity can disrupt normal cell-cycle control and allow precancerous changes to develop.

The test is therefore designed to identify people who are at increased risk before cancer develops. It often becomes abnormal earlier than a Pap test because viral infection can be detected before cells show obvious microscopic changes.

High-risk HPV testing is different from testing for the low-risk HPV types that cause most genital warts. A cervical screening assay usually focuses on the oncogenic group rather than all HPV types.

It is also different from a biopsy. A positive screening test tells the clinician that risk is elevated. A biopsy taken during colposcopy can determine whether a lesion is CIN1, CIN2, CIN3, adenocarcinoma in situ, or invasive cancer.

Cervical screening increasingly uses HPV as the primary test. In other settings, HPV testing is performed together with cytology, known as cotesting, or after an abnormal Pap result. A more focused HPV 16 and HPV 18 test can provide genotype-specific risk information within the broader high-risk result.

How Cervical HPV Screening Is Done

A clinician-collected HPV sample is usually obtained during a pelvic examination. A speculum is placed so the cervix can be seen, and a small brush or sampling device collects cells from the cervix. The sample is placed in a preservative and sent to the laboratory.

The same specimen can often be used for HPV testing and cytology. Whether both are performed immediately depends on the screening strategy.

Primary HPV testing

In primary HPV screening, the HPV result comes first. If it is negative, the person returns at the recommended screening interval. If it is positive, the laboratory or clinician uses genotype information, cytology, or another triage method to determine the next step.

Cotesting

Cotesting combines an HPV test with a Pap test. The two results are interpreted together. For example, HPV positivity with normal cytology has a different risk profile from HPV positivity with HSIL cytology.

Self-collected vaginal sampling

Selected approved programs now permit self-collected vaginal specimens for primary HPV testing in health care settings. This can improve access for people who have difficulty with a speculum examination. Clinician-collected cervical specimens remain preferred in many situations because cytology, colposcopy-related sampling, and some follow-up pathways require cervical material.

A self-collected sample is not simply interchangeable with every cervical test. Current guidance recommends different follow-up intervals for some negative self-collected tests, and positive results may require a clinician-collected cervical specimen or colposcopy.

No fasting is required. Menstruation, vaginal medications, recent intercourse, and collection technique can affect practical scheduling or specimen quality, so the clinic’s instructions should be followed. If the laboratory reports an invalid result, repeat collection is generally needed rather than interpreting it as negative.

High-Risk HPV Types and Genotypes

Not all high-risk HPV types carry the same risk. HPV 16 is the most strongly associated with cervical precancer and cancer. HPV 18 is also high risk and has a notable association with adenocarcinoma. These two types are often reported separately because management is more aggressive.

Extended genotyping can provide additional risk groups beyond HPV 16 and 18. Current guidance recognizes meaningful differences among types such as HPV 45, HPV 31, HPV 33/58, HPV 52, HPV 35/39/68, HPV 51, and HPV 56/59/66. The exact groupings depend on the approved assay.

This matters because a report that says “other high-risk HPV positive” may include viruses with different risks. Newer tests can sometimes distinguish enough types to tailor follow-up more precisely.

The broad principle is:

  • HPV 16 or 18: usually direct colposcopy.
  • Several other carcinogenic genotypes: often triage with cytology or dual stain.
  • Lower-risk groups within the carcinogenic spectrum: in selected situations, repeat HPV testing in 1 year may be appropriate if no higher-risk finding is present.

These are not do-it-yourself rules. Prior CIN2+, previous treatment, pregnancy, immune compromise, and high-grade cytology can override a simple genotype pathway.

HPV vaccination reduces the chance of infection with major cancer-causing types, including HPV 16 and 18. However, vaccinated people still require recommended screening because vaccination does not cover every carcinogenic type and does not treat infections acquired before vaccination.

What a Positive HPV Test Means

A positive result means high-risk HPV genetic material was detected in the sample. It does not tell how long the infection has been present, whether it was recently acquired, or which partner transmitted it.

HPV can become undetectable and later be detected again. A new positive test after several negative years may represent a new infection, intermittent detection of an older infection, or reactivation. Standard clinical tests cannot reliably distinguish these possibilities.

The main clinical question is the risk of current or future cervical precancer. That risk increases with:

  • HPV 16 or HPV 18 positivity;
  • persistent positivity on repeated tests;
  • abnormal cytology, especially high-grade findings;
  • a history of CIN2, CIN3, or adenocarcinoma in situ;
  • immune suppression;
  • smoking and certain other cofactors.

A positive test in an otherwise average-risk person often triggers triage rather than immediate treatment. Treatment is aimed at proven precancerous lesions, not the HPV infection itself.

There is no clinically useful “HPV level” analogous to a tumor-marker concentration. Some laboratory platforms generate cycle thresholds or other analytic signals, but routine management is based on validated positive/negative results, genotype, and risk history rather than a viral-load number.

There is also no approved medication that reliably clears cervical HPV. Products marketed as HPV-clearing supplements should not replace surveillance. The most important actions are completing recommended follow-up, avoiding tobacco, and receiving HPV vaccination when eligible.

What a Negative HPV Test Means

A negative high-risk HPV result means none of the carcinogenic types targeted by that assay were detected at a level that meets the test’s positive threshold. In average-risk screening, this result is highly reassuring because the chance of clinically important cervical precancer in the near term is low.

The next screening interval is not identical for everyone. It depends on age, national guidelines, whether the test was primary HPV screening or cotesting, whether a clinician or the patient collected the sample, and whether there is a history of high-grade disease.

A negative result does not mean the person can never develop HPV-related disease. New infection can occur later, and rare false-negative results can happen because of inadequate sampling or very low viral concentration.

More importantly, screening recommendations for someone previously treated for CIN2+ differ from those for an average-risk person. Long-term surveillance may continue for many years because prior high-grade precancer changes future risk.

A negative screening test also should not be used to explain away symptoms. Bleeding after sex, bleeding between periods, postmenopausal bleeding, persistent watery or bloody discharge, or unexplained pelvic pain requires evaluation. Screening tests are optimized for people without symptoms; diagnostic workup follows a different pathway.

Follow-Up After an Abnormal Result

Follow-up is risk based. The same positive HPV result can lead to different management depending on genotype, cytology, and previous results.

Colposcopy

Colposcopy uses magnification to examine the cervix after acetic acid is applied. Areas that look abnormal can be biopsied. HPV 16 or HPV 18 positivity commonly meets the risk threshold for colposcopy even when cytology is negative.

Cytology triage

For some non-16/18 high-risk HPV results, a Pap test helps determine whether immediate colposcopy or short-interval surveillance is appropriate. High-grade cytology generally raises risk substantially.

p16/Ki-67 dual stain

Dual stain detects p16 and Ki-67 in the same cervical cell, a pattern that suggests an HPV infection is causing abnormal cell-cycle activity. Current guidance accepts dual stain as a triage option for many HPV-positive results. A positive dual stain generally supports colposcopy; a negative result can support 1-year follow-up in appropriate lower-risk situations.

HPV 16 and HPV 18 are important exceptions: current dual-stain guidance still directs these genotypes to colposcopy even if dual stain is negative. The Ki-67 cervical dysplasia test is therefore best understood as a risk-triage tool, not a test that cancels genotype risk.

Biopsy and pathology

If biopsy shows high-grade squamous intraepithelial lesion, the pathology report may use p16 staining to support classification in certain cases. A separate p16 IHC test is performed on tissue, whereas dual stain is usually a cytology-based triage test.

Treatment depends on the lesion. CIN1 often undergoes observation. CIN2 may be treated or, in carefully selected patients, observed. CIN3 generally requires treatment. Invasive cancer requires gynecologic oncology care.

Screening Limits and Practical Next Steps

The HPV test is highly effective because it identifies the biologic cause of most cervical cancers, but it still has limits. A positive result can create anxiety even though cancer is uncommon among screen-positive individuals. A negative result can create false reassurance if symptoms or high-risk history are ignored.

After receiving a result, review four details:

  1. Was the entire high-risk HPV test positive or negative?
  2. Were HPV 16 and HPV 18 reported separately?
  3. Was cytology, dual stain, or extended genotyping performed?
  4. What prior HPV, Pap, biopsy, or treatment history changes the current risk?

Keeping copies of results is valuable because modern management depends heavily on history. The risk associated with today’s HPV-positive test may be lower after a documented prior negative HPV test than after several years of persistent positivity.

People who have completed treatment for high-grade precancer should not assume they can return to routine intervals after one negative test. Follow-up is longer and more intensive than average-risk screening.

An abnormal HPV result can also be emotionally difficult because HPV is sexually transmitted. It is useful to remember that the test cannot date the infection. It cannot establish infidelity, and it does not imply poor hygiene or risky behavior. The medical focus should remain on prevention through appropriate follow-up.

If HPV vaccination is still recommended or can be considered for the person’s age, vaccination may still provide benefit against types not previously acquired. It does not clear an existing positive test but can reduce future infection risk.

For an integrated view of how HPV, cytology-related biomarkers, and pathology work together, the cervical cancer biomarker panel can help clarify which tests are used for screening, triage, and diagnosis.

Situations that need individualized screening

Average-risk screening recommendations do not apply unchanged to everyone. People with a history of CIN2, CIN3, adenocarcinoma in situ, cervical cancer, significant immune suppression, or certain prenatal exposures may need a different schedule. People who have had a hysterectomy also need advice based on whether the cervix was removed and whether there was prior high-grade cervical disease. Age alone is therefore not enough to decide whether screening can safely stop.

Screening can also be delayed or missed when pelvic examinations are difficult because of pain, trauma history, disability, gender dysphoria, or access barriers. Self-collection may help some people overcome those barriers, but a positive test can still require a cervical examination. Discussing these issues before testing can make the follow-up plan more realistic.

Finally, an HPV-positive result should be viewed as a prevention opportunity rather than a prediction that cancer will develop. The screening system works because it identifies elevated risk early enough for surveillance, biopsy, and treatment of precancer. Keeping follow-up appointments has far more clinical value than repeatedly retesting too soon in hopes that the virus will become negative. If a recommended colposcopy or repeat test is missed, contact the clinic rather than waiting for the next routine screening cycle. Risk-based intervals are chosen to balance early detection with avoiding unnecessary procedures, so both excessive testing and delayed testing can create problems. When results come from different health systems, bringing prior records to the next appointment can prevent duplicated procedures and help the clinician apply the correct risk estimate. Prior treatment for high-grade disease is especially important to document because it can alter surveillance for decades.

Keeping prior HPV, cytology, colposcopy, and treatment results available is especially important because current management is risk based. The same positive HPV result can lead to different follow-up when a person has a recent negative HPV test, a prior high-grade lesion, or incomplete surveillance. Accurate records help prevent both unnecessary procedures and delayed evaluation.

References

Disclaimer

Cervical HPV results should be interpreted with age, genotype, cytology or other triage findings, prior screening results, and any history of cervical precancer or treatment. A positive HPV test does not diagnose cancer, and a negative test does not replace diagnostic evaluation for abnormal bleeding or other symptoms. Follow the specific surveillance or colposcopy recommendation from your clinician.

RELATED ARTICLESMORE FROM AUTHOR